How the answers frame AbbVie
In this snapshot (measured 2026-09-28, five assistants), AbbVie was named in 8 of 25 answers. ChatGPT named it in 2, Claude in 1, Gemini in 2 and Grok in 3. Perplexity did not name it in any answer. Pfizer, Johnson & Johnson and Merck were named more often, and Eli Lilly less often.
The framing changed with the question. On trust, Claude cited AbbVie's score on the Bowen Craggs Index of corporate digital communications. Gemini listed it among companies whose performance patient groups assess in the PatientView report. Grok said Newsweek's 2026 trustworthiness ranking placed it in the upper ranks. On pricing, Gemini and Grok grouped AbbVie with other large manufacturers criticized over drug prices, and ChatGPT included it in a list of companies caught up in pricing criticism. On patient access, Grok described AbbVie's myAbbVie Assist program as strong across several therapy areas. On litigation, ChatGPT listed 'Allergan / AbbVie' among companies appearing in opioid-related enforcement and litigation lists.
AbbVie was mostly a list entry. The answers' credit tags for it are mostly 'not substantive' (four mentions). The rest split across price and value (two), customer experience (one) and safety and compliance (one).
Often scrutinized for its pricing strategies related to its flagship products, such as treatments for autoimmune conditions.
What the press is saying
PeakMetrics' news index shows 11,036 mentions of AbbVie over the last 30 days, with the brand in the headline of 2,289. That is heavier coverage than Moderna (10,024) and lighter than Merck (20,326), Eli Lilly (19,280) and Pfizer (18,663).
The recent headlines are mostly about products and money. They cover real-world data for the psychiatric drug Vraylar, a phase 3 migraine result for atogepant, a stock comparison with Novo Nordisk, and a piece on its tax rate against peers. One headline covers a court dispute over how the Botox product is classified under the Inflation Reduction Act, and suggests Merck could review its own exposure.
…companies like AbbVie, Merck (Germany), Takeda, Amgen, and CSL appear in the upper ranks.
The gap
The two stories overlap very little. The press storyline in these headlines is pipeline results, investor comparisons and one pricing-policy lawsuit. The assistants answered reputation questions and drew on rankings, congressional pricing scrutiny, patient-assistance programs and opioid-era litigation lists. None of the eight answers mentioned Vraylar, atogepant or the Botox dispute.
Heavy news volume did not translate into a consistent AI role. Merck and Eli Lilly have more coverage than AbbVie, yet Eli Lilly appeared in fewer of these answers. Moderna has similar coverage and appeared in none. These are single snapshots, so this shows only that news volume and AI visibility measured different things here.
Strong across neurology, rheumatology, and gastroenterology; high income thresholds (up to 500% FPL in some cases).
What to watch
For a comms team, the takeaway from this snapshot is that AbbVie's reputation in the assistants depends on which question is asked. Answers on trust drew on third-party rankings and patient-group surveys. Answers on pricing and litigation drew on congressional and enforcement sources. Patient-access answers drew on program comparisons. Each cluster is worth reading in full to see which sources the assistants lean on.
Two further points are worth tracking. Perplexity did not name AbbVie in any answer here. The Botox classification dispute is heavily present in the press index but absent from the answers, so it is worth checking whether it starts to appear in pricing-related answers. Because live answers vary between runs, repeat the benchmark questions before treating any of this as a pattern.